BIO

After completing his degree in Electronics Engineering from the Tecnológico de Lerdo (ITSL, Durango, Mexico), Pablo Guevara embarked on a journey of scientific exploration. In 2019, he completed his Master's and Doctoral degrees in Physics and Biomedical Engineering at the esteemed Cinvestav-IPN in Monterrey, Mexico. During this time, he immersed himself in a collaborative, multidisciplinary environment, gaining expertise in bioassays and biophysics applied to microfluidic systems. His contributions to this critical field were recognized in 2023 when he secured an MSCA COFUND Postdoctoral fellowship to further his research at the Microfluidics Cluster UPV/EHU in Spain.

PROJECT

Anticancer drugs induce cardiac diseases in patients undergoing therapy. Currently, there are no tools to evaluate cardiac risk from a new anticancer therapy. Human-induced pluripotent stem cells (hiPSCs) enable the generation of cardiac cells identical to those of the patients themselves, and it is already proven these derived cardiac cells are capable of reproducing the response of the patient versus drug. The bio-sensing platform SCADA, enable real-time, digital, specific, and dynamic measurements of cell adhesion, detachment, and staining with single-cell resolution using a small number of cells. Combining the SCADA methodology, hiPSC-derived cardio myocytes and microfluidics, we will develop an integrated testing system, termed Cardiotoxicity SCADA Instrument (CSI), to evaluate the cardiotoxicity of new developing drugs.

This is a highly multidisciplinary project combining fundamental scientific research on molecular biology, surface chemistry, microfluidics, and miniaturized optical and electronic systems.

The Microfluidics Cluster UPV/EHU in collaboration with CIMA at Universidad de Navarra and a SME will lead this project.